#LCSM Transcript
Healthcare social media transcript of the #LCSM hashtag.
– ().
See #LCSM Influencers/Analytics.
| Profile | Tweet |
|---|---|
 | Ari E. Marciscano, MD @AE_MarciscanoMD RT @JAMAOnc: Rand ph2 trial of pembro vs. stereotactic body radiation therapy (SBRT) to a lesion before pembro for adv NSCLC shows doubling of resp rate & longer PFS & OS, though non-signif, w SBRT; main diff in PD-L1 neg tumors https://t.co/cEmkuo3hkh #LCSM #RadOnc |
| Ari E. Marciscano, MD @AE_MarciscanoMD RT @LChen_MD: First randomized trial to demonstrate PFS and OS benefit of SBRT to ICI in metastatic NSCLC - ORR from 18% to 36% with the addition of 8 Gy x3 prior to Pembro @JAMAOnc |
 | Bob Steele @steele_bob RT @LungCancerFaces: Remember #LCSM friends, for tonight’s chat we will use the #CANCERSM hashtag! https://t.co/pesMIAior5 |
 | Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Please remember to include #cancersm in ALL your tweets so the other chat participants can see them. If you are new to Twitter, or need a refresher, please read the #LCSM primer on participating in a Twitter chat -https://t.co/shziI4sXdT |
 | Janet Freeman-Daily @JFreemanDaily Hi everyone! Welcome to the pancancer #CANCERSM chat on "Basics of Biomarkers Testing"! Remember to us #cancersm instead of other cancer hashtags (like #LCSM #BCSM #BTSM @GYCSM etc.) |
 | #LCSM Chat @lcsmchat Deana Hendrickson @LungCancerFaces in Los Angeles here. Calling all #lcsm lung cancer people to tonight’s #CANCERSM Chat on biomarkers. |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @LungCancerFaces: Remember #LCSM friends, for tonight’s chat we will use the #CANCERSM hashtag! https://t.co/pesMIAior5 |
 | Christina Lizaso @btrfly12 RT @TimAllenMDJD: Please remember to include #cancersm in ALL your tweets so the other chat participants can see them. If you are new to Twitter, or need a refresher, please read the #LCSM primer on participating in a Twitter chat -https://t.co/shziI4sXdT |
| #LCSM Chat @lcsmchat RT @TimAllenMDJD: Please remember to include #cancersm in ALL your tweets so the other chat participants can see them. If you are new to Twitter, or need a refresher, please read the #LCSM primer on participating in a Twitter chat -https://t.co/shziI4sXdT |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: Hi everyone! Welcome to the pancancer #CANCERSM chat on "Basics of Biomarkers Testing"! Remember to us #cancersm instead of other cancer hashtags (like #LCSM #BCSM #BTSM @GYCSM etc.) |
 | Ashley Love Sumrall, MD, FACP, FASCO @AshleySumrallMD Screening saves. #lcsm @mamawheel @LevineCancer #myLCI |
| Janet Freeman-Daily @JFreemanDaily @theNCI There are also tumor markers in certain bodily fluids other than blood -- for #lungcancer patients, pleural fluid often also contains tumor cells that can undergo biomarker testing. #LCSM #cancersm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: @theNCI There are also tumor markers in certain bodily fluids other than blood -- for #lungcancer patients, pleural fluid often also contains tumor cells that can undergo biomarker testing. #LCSM #cancersm |
 | Darcy Burbage, DNP, RN, AOCN @DarcyBurbage RT @JFreemanDaily: @theNCI There are also tumor markers in certain bodily fluids other than blood -- for #lungcancer patients, pleural fluid often also contains tumor cells that can undergo biomarker testing. #LCSM #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @JFreemanDaily: @theNCI There are also tumor markers in certain bodily fluids other than blood -- for #lungcancer patients, pleural fluid often also contains tumor cells that can undergo biomarker testing. #LCSM #cancersm |
 | Matthew Katz, MD 🟦 @subatomicdoc RT @JFreemanDaily: @theNCI There are also tumor markers in certain bodily fluids other than blood -- for #lungcancer patients, pleural fluid often also contains tumor cells that can undergo biomarker testing. #LCSM #cancersm |
| Janet Freeman-Daily @JFreemanDaily Many non-small cell #lungcancer people also identify with biomarkers--EGFR, ALK, ROS1, BRAF, NTRK, KRAS, RET .... #LCSM #cancersm |
 | National Cancer Institute @theNCI RT @JFreemanDaily: @theNCI There are also tumor markers in certain bodily fluids other than blood -- for #lungcancer patients, pleural fluid often also contains tumor cells that can undergo biomarker testing. #LCSM #cancersm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: Many non-small cell #lungcancer people also identify with biomarkers--EGFR, ALK, ROS1, BRAF, NTRK, KRAS, RET .... #LCSM #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @JFreemanDaily: Many non-small cell #lungcancer people also identify with biomarkers--EGFR, ALK, ROS1, BRAF, NTRK, KRAS, RET .... #LCSM #cancersm |
| Darcy Burbage, DNP, RN, AOCN @DarcyBurbage RT @JFreemanDaily: Many non-small cell #lungcancer people also identify with biomarkers--EGFR, ALK, ROS1, BRAF, NTRK, KRAS, RET .... #LCSM #cancersm |
| National Cancer Institute @theNCI RT @JFreemanDaily: Many non-small cell #lungcancer people also identify with biomarkers--EGFR, ALK, ROS1, BRAF, NTRK, KRAS, RET .... #LCSM #cancersm |
 | Vin @wakeup_vin RT @JFreemanDaily: Many non-small cell #lungcancer people also identify with biomarkers--EGFR, ALK, ROS1, BRAF, NTRK, KRAS, RET .... #LCSM #cancersm |
 | HF. @Hfahad53 RT @JFreemanDaily: @theNCI There are also tumor markers in certain bodily fluids other than blood -- for #lungcancer patients, pleural fluid often also contains tumor cells that can undergo biomarker testing. #LCSM #cancersm |
 | PF Anderson @pfanderson@disabled.social @pfanderson RT @JFreemanDaily: Many non-small cell #lungcancer people also identify with biomarkers--EGFR, ALK, ROS1, BRAF, NTRK, KRAS, RET .... #LCSM #cancersm |
| Vin @wakeup_vin RT @JFreemanDaily: @theNCI There are also tumor markers in certain bodily fluids other than blood -- for #lungcancer patients, pleural fluid often also contains tumor cells that can undergo biomarker testing. #LCSM #cancersm |
| Christina Lizaso @btrfly12 RT @JFreemanDaily: Many non-small cell #lungcancer people also identify with biomarkers--EGFR, ALK, ROS1, BRAF, NTRK, KRAS, RET .... #LCSM #cancersm |
 | Kim Moran-MacIntosh 🇨🇦 🍀 @Kamacintosh RT @EGFRResisters: The Call for Abstracts is open for the First Annual @EGFRResisters Research Summit! If you are junior faculty or a fellow working in the #EGFR space in North America, go to @EGFRSummit to submit your abstract for a chance to join us in Chicago November 15-16. #lcsm #lungcancer |
| National Cancer Institute @theNCI T3 In non-small cell lung cancer, an analysis of mutations in the EGFR gene can help doctors determine a patient’s treatment and estimate prognosis. #cancersm #lcsm |
 | Pub Health Monitor @monitor_PH RT @theNCI: T3 In non-small cell lung cancer, an analysis of mutations in the EGFR gene can help doctors determine a patient’s treatment and estimate prognosis. #cancersm #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @theNCI: T3 In non-small cell lung cancer, an analysis of mutations in the EGFR gene can help doctors determine a patient’s treatment and estimate prognosis. #cancersm #lcsm |
| Kim Moran-MacIntosh 🇨🇦 🍀 @Kamacintosh RT @JFreemanDaily: @theNCI There are also tumor markers in certain bodily fluids other than blood -- for #lungcancer patients, pleural fluid often also contains tumor cells that can undergo biomarker testing. #LCSM #cancersm |
| #LCSM Chat @lcsmchat RT @theNCI: T3 In non-small cell lung cancer, an analysis of mutations in the EGFR gene can help doctors determine a patient’s treatment and estimate prognosis. #cancersm #lcsm |
| Kim Moran-MacIntosh 🇨🇦 🍀 @Kamacintosh RT @IASLC: Discover the latest scientific developments in lung cancer & thoracic oncology at the IASLC 2019 World Conference on Lung Cancer. Take part in the journey to fight lung cancer --> https://t.co/iuCqdFiBVH Registration savings ends July 19, 2019. #LCSM #LungCancer #WCLC19 https://t.co/gcce15fIgp |
| Kim Moran-MacIntosh 🇨🇦 🍀 @Kamacintosh RT @IASLC: Participate in the premier conference on lung cancer & thoracic oncology and discuss the latest scientific breakthroughs in lung cancer research with industry leaders. Register now --> https://t.co/iuCqdFiBVH Registration savings ends July 19, 2019. #LCSM #LungCancer #WCLC19 https://t.co/3ZzdLFHSsN |
 | Henning Willers, MD @HenningWillers T3 in lung cancer oncogenic alterations in EGFR ALK ROS1 RET et cetera determine treatment choicces #lcsm #cancersm |
| PF Anderson @pfanderson@disabled.social @pfanderson RT @theNCI: T3 In non-small cell lung cancer, an analysis of mutations in the EGFR gene can help doctors determine a patient’s treatment and estimate prognosis. #cancersm #lcsm |
 | Laronica Conway @louisianagirl91 Great collaboration!!! 👍🏾 #LCSM #CANCERSM |
| #LCSM Chat @lcsmchat RT @HenningWillers: T3 in lung cancer oncogenic alterations in EGFR ALK ROS1 RET et cetera determine treatment choicces #lcsm #cancersm |
| Bob Steele @steele_bob RT @louisianagirl91: Great collaboration!!! 👍🏾 #LCSM #CANCERSM |
| Janet Freeman-Daily @JFreemanDaily @theNCI Analysis of mutations in EGFR+ NSCLC (and other oncogene-driven cancers) can also help determine how to treat resistance to targeted therapies. #LCSM #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @louisianagirl91: Great collaboration!!! 👍🏾 #LCSM #CANCERSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @HenningWillers: T3 in lung cancer oncogenic alterations in EGFR ALK ROS1 RET et cetera determine treatment choicces #lcsm #cancersm |
| National Cancer Institute @theNCI RT @JFreemanDaily: @theNCI Analysis of mutations in EGFR+ NSCLC (and other oncogene-driven cancers) can also help determine how to treat resistance to targeted therapies. #LCSM #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @JFreemanDaily: @theNCI Analysis of mutations in EGFR+ NSCLC (and other oncogene-driven cancers) can also help determine how to treat resistance to targeted therapies. #LCSM #cancersm |
 | EGFR Resisters @EGFRResisters RT @ivybelkins: In my latest article for @LungCancer_HU, I discuss my own dental issues and wonder if they are connected to #lungcancer treatment. #lcsm @EGFRResisters |
| Henning Willers, MD @HenningWillers RT @JFreemanDaily: @theNCI Analysis of mutations in EGFR+ NSCLC (and other oncogene-driven cancers) can also help determine how to treat resistance to targeted therapies. #LCSM #cancersm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: @theNCI Analysis of mutations in EGFR+ NSCLC (and other oncogene-driven cancers) can also help determine how to treat resistance to targeted therapies. #LCSM #cancersm |
| EGFR Resisters @EGFRResisters @ivybelkins latest article @LungCancer_HU discusses Dental Issues and the connection to Treatments #lcsm #LungCancer |
| EGFR Resisters @EGFRResisters RT @ivybelkins: The Call for Abstracts is open for the First Annual @EGFRResisters Research Summit! If you are junior faculty or a fellow working in the #EGFR space in North America, go to @EGFRSummit to submit your abstract for a chance to join us in Chicago November 15-16. #lcsm #lungcancer |
| Janet Freeman-Daily @JFreemanDaily Though biomarker testing is in @NCCN guidelines for NSCLC, recent estimates say at most 60% of eligible patients are tested for EGFR (despite having FDA-approved treatments). % for other NSCLC genomic drivers is even less. Frustrating! #LCSM #cancersm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: Though biomarker testing is in @NCCN guidelines for NSCLC, recent estimates say at most 60% of eligible patients are tested for EGFR (despite having FDA-approved treatments). % for other NSCLC genomic drivers is even less. Frustrating! #LCSM #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @JFreemanDaily: Though biomarker testing is in @NCCN guidelines for NSCLC, recent estimates say at most 60% of eligible patients are tested for EGFR (despite having FDA-approved treatments). % for other NSCLC genomic drivers is even less. Frustrating! #LCSM #cancersm |
| Henning Willers, MD @HenningWillers RT @JFreemanDaily: Though biomarker testing is in @NCCN guidelines for NSCLC, recent estimates say at most 60% of eligible patients are tested for EGFR (despite having FDA-approved treatments). % for other NSCLC genomic drivers is even less. Frustrating! #LCSM #cancersm |
 | @MyelomaTeacher - Cindy Chmielewski @MyelomaTeacher RT @JFreemanDaily: Though biomarker testing is in @NCCN guidelines for NSCLC, recent estimates say at most 60% of eligible patients are tested for EGFR (despite having FDA-approved treatments). % for other NSCLC genomic drivers is even less. Frustrating! #LCSM #cancersm |
 | Liz Salmi @TheLizArmy RT @JFreemanDaily: Though biomarker testing is in @NCCN guidelines for NSCLC, recent estimates say at most 60% of eligible patients are tested for EGFR (despite having FDA-approved treatments). % for other NSCLC genomic drivers is even less. Frustrating! #LCSM #cancersm |
| Henning Willers, MD @HenningWillers @JFreemanDaily @NCCN T3 moreover #lungcancer patients with non-metastatic disease are even less often tested for these mutations #cancersm #lcsm |
| Christina Lizaso @btrfly12 RT @JFreemanDaily: Though biomarker testing is in @NCCN guidelines for NSCLC, recent estimates say at most 60% of eligible patients are tested for EGFR (despite having FDA-approved treatments). % for other NSCLC genomic drivers is even less. Frustrating! #LCSM #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @HenningWillers: @JFreemanDaily @NCCN T3 moreover #lungcancer patients with non-metastatic disease are even less often tested for these mutations #cancersm #lcsm |
| #LCSM Chat @lcsmchat RT @HenningWillers: @JFreemanDaily @NCCN T3 moreover #lungcancer patients with non-metastatic disease are even less often tested for these mutations #cancersm #lcsm |
| Matthew Katz, MD 🟦 @subatomicdoc RT @HenningWillers: @JFreemanDaily @NCCN T3 moreover #lungcancer patients with non-metastatic disease are even less often tested for these mutations #cancersm #lcsm |
| Henning Willers, MD @HenningWillers @subatomicdoc T3 good one, small cell cancer by IHC stains would make choice against surgery #lcsm #cancersm |
| #LCSM Chat @lcsmchat RT @HenningWillers: @subatomicdoc T3 good one, small cell cancer by IHC stains would make choice against surgery #lcsm #cancersm |
| Janet Freeman-Daily @JFreemanDaily @TheLizArmy @TimAllenMDJD Pathology in #lungcancer still requires immunohistochemistry to determine type of lung cancer. Biomarkers are not yet useful in small cell lung cancer, except for clinical trial enrollment. #LCSM #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @JFreemanDaily: @TheLizArmy @TimAllenMDJD Pathology in #lungcancer still requires immunohistochemistry to determine type of lung cancer. Biomarkers are not yet useful in small cell lung cancer, except for clinical trial enrollment. #LCSM #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @HenningWillers: @subatomicdoc T3 good one, small cell cancer by IHC stains would make choice against surgery #lcsm #cancersm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: @TheLizArmy @TimAllenMDJD Pathology in #lungcancer still requires immunohistochemistry to determine type of lung cancer. Biomarkers are not yet useful in small cell lung cancer, except for clinical trial enrollment. #LCSM #cancersm |
| Janet Freeman-Daily @JFreemanDaily @HenningWillers Technically speaking, CT and PET scans are biomarkers. They would help determine whether surgery is possible. #LCSM #cancersm |
 | Dennis Keim @denniskeim RT @JFreemanDaily: Many non-small cell #lungcancer people also identify with biomarkers--EGFR, ALK, ROS1, BRAF, NTRK, KRAS, RET .... #LCSM #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @JFreemanDaily: @HenningWillers Technically speaking, CT and PET scans are biomarkers. They would help determine whether surgery is possible. #LCSM #cancersm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: @HenningWillers Technically speaking, CT and PET scans are biomarkers. They would help determine whether surgery is possible. #LCSM #cancersm |
 | jaime rueda @Jr121014921 RT @JFreemanDaily: Many non-small cell #lungcancer people also identify with biomarkers--EGFR, ALK, ROS1, BRAF, NTRK, KRAS, RET .... #LCSM #cancersm |
| Janet Freeman-Daily @JFreemanDaily @HenningWillers @subatomicdoc Not necessarily--surgery is still an option for some SCLC patients per NCCN guidelines. #LCSM #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @JFreemanDaily: @HenningWillers @subatomicdoc Not necessarily--surgery is still an option for some SCLC patients per NCCN guidelines. #LCSM #cancersm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: @HenningWillers @subatomicdoc Not necessarily--surgery is still an option for some SCLC patients per NCCN guidelines. #LCSM #cancersm |
| Matthew Katz, MD 🟦 @subatomicdoc @JFreemanDaily @HenningWillers True, but it still may play a role in opting for surgery. Also plays a role in the conversation about prophylactic cranial irradiation #cancersm #lcsm |
| Henning Willers, MD @HenningWillers @JFreemanDaily @subatomicdoc T3 correct, for the rare stage I SCLC finding this at the time of needle biopsy or wedge resection this is still a good option! (stage II more controversial) #cancersm #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Glad you are here, @EdenLake! #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @subatomicdoc: @JFreemanDaily @HenningWillers True, but it still may play a role in opting for surgery. Also plays a role in the conversation about prophylactic cranial irradiation #cancersm #lcsm |
| #LCSM Chat @lcsmchat RT @subatomicdoc: @JFreemanDaily @HenningWillers True, but it still may play a role in opting for surgery. Also plays a role in the conversation about prophylactic cranial irradiation #cancersm #lcsm |
| Matthew Katz, MD 🟦 @subatomicdoc RT @HenningWillers: @JFreemanDaily @subatomicdoc T3 correct, for the rare stage I SCLC finding this at the time of needle biopsy or wedge resection this is still a good option! (stage II more controversial) #cancersm #lcsm |
| #LCSM Chat @lcsmchat RT @HenningWillers: @JFreemanDaily @subatomicdoc T3 correct, for the rare stage I SCLC finding this at the time of needle biopsy or wedge resection this is still a good option! (stage II more controversial) #cancersm #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @HenningWillers: @JFreemanDaily @subatomicdoc T3 correct, for the rare stage I SCLC finding this at the time of needle biopsy or wedge resection this is still a good option! (stage II more controversial) #cancersm #lcsm |
| Janet Freeman-Daily @JFreemanDaily @israhkhan We have lots of data about mutations in SCLC. Unfortunately, we haven't identified one or two predominant mutations to target. SCLC is really hetereogenous. #LCSM #cancersm |
 | Rachael @PollywogPrinces Sorry I'm late. Dinner and hurricane prep tonight! #lcsm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: @israhkhan We have lots of data about mutations in SCLC. Unfortunately, we haven't identified one or two predominant mutations to target. SCLC is really hetereogenous. #LCSM #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @JFreemanDaily: @israhkhan We have lots of data about mutations in SCLC. Unfortunately, we haven't identified one or two predominant mutations to target. SCLC is really hetereogenous. #LCSM #cancersm |
| Ashley Love Sumrall, MD, FACP, FASCO @AshleySumrallMD @peggyddennis @TimAllenMDJD The issue is that tumors evolve. Multiple pubs show that biomarkers change. Look at #BATTLE in #lcsm #cancersm |
| Darcy Burbage, DNP, RN, AOCN @DarcyBurbage RT @JFreemanDaily: @israhkhan We have lots of data about mutations in SCLC. Unfortunately, we haven't identified one or two predominant mutations to target. SCLC is really hetereogenous. #LCSM #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @AshleySumrallMD: @peggyddennis @TimAllenMDJD The issue is that tumors evolve. Multiple pubs show that biomarkers change. Look at #BATTLE in #lcsm #cancersm |
| Bob Steele @steele_bob RT @AshleySumrallMD: @peggyddennis @TimAllenMDJD The issue is that tumors evolve. Multiple pubs show that biomarkers change. Look at #BATTLE in #lcsm #cancersm |
| #LCSM Chat @lcsmchat RT @AshleySumrallMD: @peggyddennis @TimAllenMDJD The issue is that tumors evolve. Multiple pubs show that biomarkers change. Look at #BATTLE in #lcsm #cancersm |
| Janet Freeman-Daily @JFreemanDaily @peggyddennis There are tens of thousands of possible mutations in human DNA. It's not possible to catch them all in one test. Best to design the test to look for those mutations that have best chance of helping to guide treatment. #LCSM #cancersm |
 | Alicia C. Staley @stales RT @JFreemanDaily: @HenningWillers Technically speaking, CT and PET scans are biomarkers. They would help determine whether surgery is possible. #LCSM #cancersm |
| Alicia C. Staley @stales RT @JFreemanDaily: @TheLizArmy @TimAllenMDJD Pathology in #lungcancer still requires immunohistochemistry to determine type of lung cancer. Biomarkers are not yet useful in small cell lung cancer, except for clinical trial enrollment. #LCSM #cancersm |
| PF Anderson @pfanderson@disabled.social @pfanderson RT @JFreemanDaily: @peggyddennis There are tens of thousands of possible mutations in human DNA. It's not possible to catch them all in one test. Best to design the test to look for those mutations that have best chance of helping to guide treatment. #LCSM #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @JFreemanDaily: @peggyddennis There are tens of thousands of possible mutations in human DNA. It's not possible to catch them all in one test. Best to design the test to look for those mutations that have best chance of helping to guide treatment. #LCSM #cancersm |
 | Jen Buhay, PhD 💙 @JenBuhayPhD RT @JFreemanDaily: Though biomarker testing is in @NCCN guidelines for NSCLC, recent estimates say at most 60% of eligible patients are tested for EGFR (despite having FDA-approved treatments). % for other NSCLC genomic drivers is even less. Frustrating! #LCSM #cancersm |
| @MyelomaTeacher - Cindy Chmielewski @MyelomaTeacher RT @AshleySumrallMD: @peggyddennis @TimAllenMDJD The issue is that tumors evolve. Multiple pubs show that biomarkers change. Look at #BATTLE in #lcsm #cancersm |
 | Aaron Maestri @aaronmaestri RT @JFreemanDaily: @TheLizArmy @TimAllenMDJD Pathology in #lungcancer still requires immunohistochemistry to determine type of lung cancer. Biomarkers are not yet useful in small cell lung cancer, except for clinical trial enrollment. #LCSM #cancersm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: @peggyddennis There are tens of thousands of possible mutations in human DNA. It's not possible to catch them all in one test. Best to design the test to look for those mutations that have best chance of helping to guide treatment. #LCSM #cancersm |
| Dennis Keim @denniskeim RT @AshleySumrallMD: @peggyddennis @TimAllenMDJD The issue is that tumors evolve. Multiple pubs show that biomarkers change. Look at #BATTLE in #lcsm #cancersm |
| Jen Buhay, PhD 💙 @JenBuhayPhD RT @ivybelkins: The Call for Abstracts is open for the First Annual @EGFRResisters Research Summit! If you are junior faculty or a fellow working in the #EGFR space in North America, go to @EGFRSummit to submit your abstract for a chance to join us in Chicago November 15-16. #lcsm #lungcancer |
| Janet Freeman-Daily @JFreemanDaily @AshleySumrallMD @peggyddennis @TimAllenMDJD And cancer evolves to develop resistance to targeted therapies. That's why rebiopsy is now more common after cancer progression in NSCLC. #lcsm #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @JFreemanDaily: @AshleySumrallMD @peggyddennis @TimAllenMDJD And cancer evolves to develop resistance to targeted therapies. That's why rebiopsy is now more common after cancer progression in NSCLC. #lcsm #cancersm |
| PF Anderson @pfanderson@disabled.social @pfanderson RT @JFreemanDaily: @AshleySumrallMD @peggyddennis @TimAllenMDJD And cancer evolves to develop resistance to targeted therapies. That's why rebiopsy is now more common after cancer progression in NSCLC. #lcsm #cancersm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: @AshleySumrallMD @peggyddennis @TimAllenMDJD And cancer evolves to develop resistance to targeted therapies. That's why rebiopsy is now more common after cancer progression in NSCLC. #lcsm #cancersm |
| Henning Willers, MD @HenningWillers RT @JFreemanDaily: @AshleySumrallMD @peggyddennis @TimAllenMDJD And cancer evolves to develop resistance to targeted therapies. That's why rebiopsy is now more common after cancer progression in NSCLC. #lcsm #cancersm |
| Christina Lizaso @btrfly12 RT @JFreemanDaily: @AshleySumrallMD @peggyddennis @TimAllenMDJD And cancer evolves to develop resistance to targeted therapies. That's why rebiopsy is now more common after cancer progression in NSCLC. #lcsm #cancersm |
| Janet Freeman-Daily @JFreemanDaily #lungcancer treatments are evolving so fast that even LC specialists have trouble keeping up--dozens of new tx approvals in just past 5 years. If your doctor does not mention biomarker testing for you NSCLC, ASK! It's stand of care! #lcsm #cancersm |
| Alicia C. Staley @stales RT @AshleySumrallMD: @peggyddennis @TimAllenMDJD The issue is that tumors evolve. Multiple pubs show that biomarkers change. Look at #BATTLE in #lcsm #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @JFreemanDaily: #lungcancer treatments are evolving so fast that even LC specialists have trouble keeping up--dozens of new tx approvals in just past 5 years. If your doctor does not mention biomarker testing for you NSCLC, ASK! It's stand of care! #lcsm #cancersm |
| Jen Buhay, PhD 💙 @JenBuhayPhD RT @JFreemanDaily: #lungcancer treatments are evolving so fast that even LC specialists have trouble keeping up--dozens of new tx approvals in just past 5 years. If your doctor does not mention biomarker testing for you NSCLC, ASK! It's stand of care! #lcsm #cancersm |
| Alicia C. Staley @stales RT @JFreemanDaily: @israhkhan We have lots of data about mutations in SCLC. Unfortunately, we haven't identified one or two predominant mutations to target. SCLC is really hetereogenous. #LCSM #cancersm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: #lungcancer treatments are evolving so fast that even LC specialists have trouble keeping up--dozens of new tx approvals in just past 5 years. If your doctor does not mention biomarker testing for you NSCLC, ASK! It's stand of care! #lcsm #cancersm |
| Janet Freeman-Daily @JFreemanDaily @AmandaHaddock @c0nc0rdance @TimAllenMDJD We have one liquid biopsy that is FDA approved for detecting a specific mutation in EGFR+ #lungcancer. #LCSM #cancersm |
| Henning Willers, MD @HenningWillers @JFreemanDaily i have definitely trouble keeping up!! #lcsm #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @JFreemanDaily: @AmandaHaddock @c0nc0rdance @TimAllenMDJD We have one liquid biopsy that is FDA approved for detecting a specific mutation in EGFR+ #lungcancer. #LCSM #cancersm |
| Henning Willers, MD @HenningWillers RT @JFreemanDaily: @AmandaHaddock @c0nc0rdance @TimAllenMDJD We have one liquid biopsy that is FDA approved for detecting a specific mutation in EGFR+ #lungcancer. #LCSM #cancersm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: @AmandaHaddock @c0nc0rdance @TimAllenMDJD We have one liquid biopsy that is FDA approved for detecting a specific mutation in EGFR+ #lungcancer. #LCSM #cancersm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @HenningWillers: @JFreemanDaily i have definitely trouble keeping up!! #lcsm #cancersm |
| Christina Lizaso @btrfly12 RT @JFreemanDaily: #lungcancer treatments are evolving so fast that even LC specialists have trouble keeping up--dozens of new tx approvals in just past 5 years. If your doctor does not mention biomarker testing for you NSCLC, ASK! It's stand of care! #lcsm #cancersm |
 | SilviaBBCCB @SilviaBBCCB RT @JFreemanDaily: @theNCI There are also tumor markers in certain bodily fluids other than blood -- for #lungcancer patients, pleural fluid often also contains tumor cells that can undergo biomarker testing. #LCSM #cancersm |
| Dennis Keim @denniskeim RT @JFreemanDaily: #lungcancer treatments are evolving so fast that even LC specialists have trouble keeping up--dozens of new tx approvals in just past 5 years. If your doctor does not mention biomarker testing for you NSCLC, ASK! It's stand of care! #lcsm #cancersm |
| Christina Lizaso @btrfly12 Fantastic job! Thanks for all you do and thanks #lcsm for rallying us all together. #cancersm |
| Janet Freeman-Daily @JFreemanDaily Thanks for sharing the link to @NCCN guidelines, @btrfly12! #cancersm #lcsm #btsm #bcsm #mmsm #ayacsm #gyncsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @JFreemanDaily: Thanks for sharing the link to @NCCN guidelines, @btrfly12! #cancersm #lcsm #btsm #bcsm #mmsm #ayacsm #gyncsm |
| Janet Freeman-Daily @JFreemanDaily Transcript for 11-Jul-2019 pancancer chat on "Basics of Biomarker Testing" is here: https://t.co/Y19PJa0dvE #cancersm #lcsm #bcsm #btsm #gyncsm #mmsm |
| National Cancer Institute @theNCI RT @JFreemanDaily: Transcript for 11-Jul-2019 pancancer chat on "Basics of Biomarker Testing" is here: Transcript for 11-Jul-2019 pancancer chat on "Basics of Biomarker Testing" is here: https://t.co/Y19PJa0dvE #cancersm #lcsm #bcsm #btsm #gyncsm #mmsm |
#LCSM content from Twitter.